Anzeige
Mehr »
Login
Donnerstag, 25.04.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Solarboom 2024: Fünf Gründe, die für diese Aktie sprechen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
243 Leser
Artikel bewerten:
(0)

DW Healthcare Partners Announces Closing of New $265 Million Third Fund

TORONTO and PARK CITY, Utah, Feb. 10, 2013 /PRNewswire/ -- DW Healthcare Partners, a healthcare-focused private equity firm, announced today that it has completed fundraising for its third fund ("DWHP III"), which has closed with $265 million of committed capital, exceeding its original target of $250 million. DWHP III investors are comprised of pension plans, foundations, fund of funds, high net-worth individuals and family trusts.

(Logo: http://photos.prnewswire.com/prnh/20130210/LA57441LOGO)

DWHP Co-Founder and Managing Director, Andrew Carragher said, "Through our partnerships with talented founders and management teams in our portfolio companies, we have been able to sustain a consistent track record of delivering above-average returns to our investors. As a result, we attracted a great deal of interest while fundraising for Fund III and are pleased that we have exceeded our target. We thank all of our limited partners for their commitment to our firm and look forward to forging new partnerships with innovators, founders, and management teams in the healthcare industry".

During the fundraising period, DWHP completed three Fund III investments, totaling approximately $80 million. Through these investments, DWHP has become equity partners with Z-Medica, a leading developer and manufacturer of innovative hemostatic agents, Health & Safety Institute, one of the leading providers of safety and emergency care content and training, and Med-Pharmex, a leading veterinary drug manufacturer.

In conjunction with raising the third fund, the firm has opened an office in Toronto, Canada. This office will enable the firm to cover the Eastern Coast of the United States and Canada more efficiently. The Toronto office is staffed with Co-Founder Andrew Carragher and Managing Director Rod Boone along with six other professionals.

DWHP's Fund III investment strategy mirrors the model of its first two funds, working as a strategic resource to founders to accelerate the growth of their businesses. DWHP's first two funds were $88 million and $162 million in size, and resulted in 16 platform company investments in the medical device, clinical research, wholesale pharmacy and outsourced healthcare service areas. For Fund III, DWHP is seeking investments in companies with EBITDA of $4 million or more. Berchwood Partners served as placement agent for DWHP Fund III.

About DW Healthcare Partners

DW Healthcare Partners is a private equity firm focused exclusively on the healthcare industry. The firm manages over $500 million in committed capital and invests in profitable healthcare companies with proven management teams. DW Healthcare Partners is led by seasoned healthcare executives with more than 110 years of combined industry experience. The firm provides the capital, strategic guidance, and acquisition expertise to help mid-to-late-stage companies realize their potential for growth. For more information, please visit www.dwhp.com.

Office addresses:


Toronto:

66 Wellington Street West, Suite 4030

Toronto, ON M5K 1J5

416 583 2420

Park City:

1413 Center Drive, Suite 220

Park City, Utah 84098

435 645 4050

Contact: Andrew Carragher
Phone: 416 583 2421
Email: andrew@dwhp.com
Website: www.dwhp.com

SOURCE DW Healthcare Partners

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2013 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.